

Every Quit Deserves a Fresh Start

Support your patients' decision to
quit smoking with **Citidaron[®]**.



Indicated for smoking cessation and
the reduction of nicotine cravings in
smokers who are willing to quit¹

**PRESCRIBING INFORMATION
& ADVERSE EVENT REPORTING
DETAILS CAN BE FOUND ON
THE BACK COVER**

 **Citidaron[®]**

Cytisinicline

Previously used name cytisine

Support your patients who are motivated to quit with a 25-day structured quit plan.

Citidaron® provides a complete 25-day treatment course in one pack, prescribed once with patients advised to stop smoking by Day 5.¹

Keeping both patient and prescriber in mind:



One pack, One prescription¹

Simplifies prescribing and dispensing, supporting immediate patient access while reducing administrative burden.



Structured 25-day treatment course¹

A 25-day treatment plan with a clear tapering schedule.



GMS Reimbursed²



Trusted in Smoking Cessation Across Europe for Over 50 Years³

Used for over 50 years in Europe to support smoking cessation, with a well-established tolerability profile.⁴



Day 5: the targeted quit date¹

Treatment includes a targeted quit date of Day 5 to support cessation.¹

Helping your patients succeed — with structured support for every quit attempt.¹

Because not every quit attempt works the first time, consider Citidaron® for patients who remain motivated to quit.

A patient dosage card is available to support daily tracking and treatment progress.



Additional HCP support and Citidaron® Dosing Guide and Patient Leaflet is available for download by scanning the QR code or by visiting [consilienthealth.ie](https://www.consilienthealth.ie)

Citidaron® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking.¹

The treatment goal of Citidaron® is the permanent cessation of the nicotine-containing products use.¹

References

1. Citidaron® Summary of product characteristics. Available at www.medicines.ie [Accessed November 2025]
2. Citidaron®, HSE reimbursable item. Available at: <https://www.sspcrs.ie/druglist/search/category/0?drugName=Citidaron> [Accessed September 2025]
3. Karnieg T, Wang X. CYTISINE for smoking cessation CMAJ 2018;190(19):E596.
4. Cahill K, Lindson N, et al. Pharmacological and electronic cigarette interventions for smoking cessation. Cochrane Database Syst Rev. 2023

Prescribing Information

Citidaron (Cytisinicline) Abbreviated Prescribing Information. Please refer to the Summary of Product Characteristics for full details.

Product name: Citidaron 1.5mg tablets

Composition: 1.5mg of Cytisinicline (previously used name: cytisine).

Indication: Smoking cessation and reduction of nicotine cravings in smokers willing to stop. Treatment goal is the permanent cessation of use of nicotine-containing products.

Posology and administration: Adults: One pack (100 tablets) is sufficient for a complete treatment course of 25 days: Day 1-3: 1 tablet every 2 hours (maximum 6 per day); Day 4-12: 1 tablet every 2.5 hours (maximum 5 per day); Day 13-16: 1 tablet every 3 hours (maximum 4 per day); Day 17-20: 1 tablet every 5 hours (maximum 3 per day); Day 21-25: 1-2 tablets a day (maximum 2 per day). Stop smoking no later than 5th day of treatment; continuing smoking may aggravate adverse reactions. In case of treatment failure, discontinue; may be resumed after 2 to 3 months.

Special populations: Renal or hepatic impairment: no clinical experience; not recommended. **Elderly (over 65 years):** limited clinical experience; not recommended. **Paediatric population (under 18 years):** Safety and efficacy not established; not recommended.

Method of administration: Orally with water.

Contraindications: Hypersensitivity to active substance or excipients; unstable angina; recent myocardial infarction or stroke; clinically significant arrhythmias; pregnancy and breastfeeding.

Warnings and precautions (see SmPC for full details): Only for patients with serious intention of weaning off nicotine. Patient should be aware that simultaneous smoking or use of nicotine-containing products could lead to aggravated adverse reactions of nicotine. Use with caution in: ischemic heart disease, heart failure, hypertension pheochromocytoma, atherosclerosis and other peripheral vascular diseases, gastric and duodenal ulcer, gastroesophageal reflux disease, hyperthyroidism, diabetes and schizophrenia. Polycyclic aromatic hydrocarbons in tobacco

smoke induce metabolism by CYP 1A2 (and possibly CYP 1A1). Stopping smoking may slow metabolism and raise blood levels of such drugs. Potentially clinically important if narrow therapeutic window, e.g. theophylline, tacrine, clozapine, ropinirole. Levels of products partly metabolised CYP1A2 e.g. imipramine, olanzapine, clomipramine, fluvoxamine, may also increase; data are lacking, clinical significance unknown. Limited data indicate metabolism of flecainide and pentazocine may be induced by smoking. Be aware of serious neuropsychiatric symptoms in patients attempting to quit smoking, with or without treatment, including: depressed mood, rarely including suicidal ideation and suicide attempt; exacerbation of underlying psychiatric illness (e.g. depression) - take care in these patients and advise accordingly. (See Pregnancy).

Pregnancy: Contraindicated. Women of childbearing potential must use highly effective contraception. If on systemically acting hormonal contraceptives, add a second barrier method.

Breastfeeding: Contraindicated. **Fertility:** No data available.

Undesirable effects: Very Common (≥1/10): change in appetite (mainly increase), weight gain, dizziness, irritability, mood changes, anxiety, sleep disorders (insomnia, drowsiness, lethargy, abnormal dreams, nightmares), headaches, tachycardia, hypertension, dry mouth, diarrhea, nausea, changes flavour, heartburn, constipation, vomiting, abdominal pain (especially in the upper abdomen), rash, myalgia, fatigue. **Common (≥1/100 to <1/10):** difficulty in concentration, slow heart rate, abdominal distension, burning tongue, malaise.

Price: <https://www.consilienthealth.ie/our-medicines/pricing-of-our-medicines/>

Legal Classification: POM.

MA number: PA22714/001/001.

Marketing Authorisation Holder: Aflofarm Farmacja Polska Sp. z o.o. CRN00D3GH, Partyzancka 133/151 Pabianice 95-200 Poland. Further information is available on request from Consilient Health Ltd, Block 2A Richview Office Park, Clonskeagh, Dublin 14. **Job Code:** IE-CYT-1(5) **Date of preparation:** November 2025

Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie.

Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.